Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Hefei, China.
The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Int Immunopharmacol. 2023 Mar;116:109755. doi: 10.1016/j.intimp.2023.109755. Epub 2023 Jan 30.
Rheumatoid arthritis (RA) is a multisystemic and inflammatory autoimmune disease characterized by joint destruction. The C-C motif chemokine receptor 2 (CCR2) is mainly expressed in monocytes and T cells, initiating their migration to sites of inflammation, ultimately leading to cartilage damage and bone destruction. CCR2 has long been considered a prospective target for treating autoimmune diseases. However, clinical studies on inhibitors or neutralizing antibodies against CCR2 in RA have exhibited limited efficacy. Recent evidence indicates that CCR2 may play different roles in RA. Hence, a comprehensive understanding regarding the role of CCR2 may facilitate the development of targeted drugs and provide novel insights for improving CCL2-mediated inflammatory diseases. This review summarizes the biological characteristics of CCR2, the related signaling pathways, and recent developments in CCR2-targeting therapeutics.
类风湿关节炎（RA）是一种多系统和炎症性自身免疫性疾病，其特征是关节破坏。C-C 基序趋化因子受体 2（CCR2）主要在单核细胞和 T 细胞中表达，启动它们向炎症部位迁移，最终导致软骨损伤和骨破坏。CCR2 长期以来一直被认为是治疗自身免疫性疾病的有前途的靶点。然而，RA 中针对 CCR2 的抑制剂或中和抗体的临床研究显示出有限的疗效。最近的证据表明，CCR2 在 RA 中可能发挥不同的作用。因此，全面了解 CCR2 的作用可能有助于开发靶向药物，并为改善 CCL2 介导的炎症性疾病提供新的见解。本综述总结了 CCR2 的生物学特性、相关信号通路以及 CCR2 靶向治疗的最新进展。
